Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
Go back to Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19| Merck & Co. (NYSE: MRK) | Delayed: 144.17 -0.54 (0.37%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $144.71 | 52 Week High | $65.46 | |||
| Open | $145.52 | 52 Week Low | $47.97 | |||
| Day High | $145.90 | P/E | 98.07 | |||
| Day Low | $143.82 | EPS | $1.47 | |||
| Volume | 1,614,432 | |||||
